Bioventus Inc. Files 8-K on Financials
Ticker: BVS · Form: 8-K · Filed: Aug 6, 2024 · CIK: 1665988
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: BVS
TL;DR
Bioventus filed an 8-K, expect financial updates soon.
AI Summary
Bioventus Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition, and filing financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing serves as an official notification to investors and the public regarding Bioventus Inc.'s financial status and operational updates.
Risk Assessment
Risk Level: low — The filing is a standard procedural report and does not contain information indicating immediate financial distress or significant risk.
Key Players & Entities
- Bioventus Inc. (company) — Registrant
- August 6, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Durham, North Carolina (location) — Address of principal executive offices
FAQ
What specific financial results or conditions are being reported by Bioventus Inc. in this 8-K?
The provided text indicates the filing is related to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not detail the specific results or conditions.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 6, 2024.
What is the principal business address of Bioventus Inc. as listed in the filing?
The principal executive offices of Bioventus Inc. are located at 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703.
Under which section of the Securities Exchange Act of 1934 is Bioventus Inc. filing this Current Report?
Bioventus Inc. is filing this Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the SIC code for Bioventus Inc. as provided in the filing?
The Standard Industrial Classification (SIC) code for Bioventus Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-08-06 07:40:31
Key Financial Figures
- $0.001 — hich registered Class A common Stock, $0.001 par value per share BVS The Nasdaq Glob
Filing Documents
- bvs-20240806.htm (8-K) — 32KB
- bioventusex-991q22024.htm (EX-99.1) — 451KB
- image_0a.jpg (GRAPHIC) — 49KB
- 0001628280-24-034976.txt ( ) — 742KB
- bvs-20240806.xsd (EX-101.SCH) — 2KB
- bvs-20240806_def.xml (EX-101.DEF) — 15KB
- bvs-20240806_lab.xml (EX-101.LAB) — 26KB
- bvs-20240806_pre.xml (EX-101.PRE) — 16KB
- bvs-20240806_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 6, 2024, Bioventus Inc. (the "Company") issued a press release announcing its financial results for the three and six months ended June 29, 2024 . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated August 6 , 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOVENTUS INC. Date: August 6, 2024 By: /s/ Anthony D'Adamio Anthony D'Adamio Senior Vice President and General Counsel